Please login to the form below

insulin glargine

This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.

Sanofi sells European generics to Advent for $2.4bn

Sanofi is in the midst of a shakedown of its business prompted by a decline in sales of its diabetes blockbuster Lantus (insulin glargine) and the failure of some other products

Latest news

Type 2 diabetes can be reversed in just four months, say researchers

calorie intake by 500 to 750 per day and continued use of glucose-controlling drugs (metformin, acarbose and in some cases basal insulin) to closely manage blood sugar levels. ... According to lead investigator Hertzel Gerstein, the team chose to use
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
Sanofi launches insulin combo Soliqua in US

Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination
Lilly and Boehringer launch first Lantus clone Basaglar in US

Eli Lilly and Boehringer Ingelheim have launched their Basaglar copy at a 15% discount to Lantus (insulin glargine), which is already facing tough competition from other insulin products such as Novo ... We know that starting insulin can be a challenging
FDA clears rival diabetes combos from Sanofi and Novo Nordisk

In the case of Xultophy, the combination is based on Novo's basal insulin Tresiba (insulin degludec) and market-leading GLP-1 agonist Victoza (liraglutide). ... In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan)

More from news
Approximately 23 fully matching, plus 105 partially matching documents found.

Latest Intelligence

Going the distance

In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Sanofi promotes diabetes expert Paul Chew to chief medical officer

position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager or AD - Medical Communications: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and benefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Editorial Director – Medical Education – Oxford: Negotiable

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager – Med Comms – London: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Programme Executive: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Scientific Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Subscribe to our email news alerts

PMHub

Add my company

Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...